Biochemistry and Molecular Biology
Molecular Analysis of Bardet-Biedl Syndrome Families:
Report of 21 Novel Mutations in 10 Genes
Jianjun Chen,1 Nizar Smaoui,2 Monia Ben Hamed Hammer,2 Xiaodong Jiao,1
S. Amer Riazuddin,3,4 Shyana Harper,5 Nicholas Katsanis,6 Sheikh Riazuddin,3,7
Habiba Chaabouni,8 Eliot L. Berson,5 and J. Fielding Hejtmancik1
PURPOSE. Bardet-Biedl syndrome (BBS) is genetically heterogeneous with 15 BBS genes currently identified, accounting for
approximately 70% of cases. The aim of our study was to define
further the spectrum of BBS mutations in a cohort of 44
European-derived American, 8 Tunisian, 1 Arabic, and 2 Pakistani families (55 families in total) with BBS.
METHODS. A total of 142 exons of the first 12 BBS-causing genes
were screened by dideoxy sequencing. Cases in which no
mutations were found were then screened for BBS13, BBS14,
BBS15, RPGRIP1L, CC2D2A, NPHP3, TMEM67, and INPP5E.
RESULTS. Forty-three mutations, including 8 frameshift mutations, 10 nonsense mutations, 4 splice site mutations, 1 deletion, and 20 potentially or probably pathogenic missense variations, were identified in 46 of the 55 families studied (84%).
Of these, 21 (2 frameshift mutations, 4 nonsense mutations, 4
splice site mutations, 1 deletion, and 10 missense variations)
were novel. The molecular genetic findings raised the possibility of triallelic inheritance in 7 Caucasian families, 1 Arabian
family, and 1 Tunisian patient. No mutations were detected for
BBS4, BBS11, BBS13, BBS14, BBS15, RPGRIP1L, CC2D2A,
NPHP3, TMEM67, or INPP5E.
CONCLUSIONS. This mutational analysis extends the spectrum of
known BBS mutations. Identification of 21 novel mutations
highlights the genetic heterogeneity of this disorder. Differences in European and Tunisian patients, including the high
frequency of the M390R mutation in Europeans, emphasize the
population specificity of BBS mutations with potential diagnostic implications. The existence of some BBS cases without
From the 1Ophthalmic Genetics and Visual Function Branch and
the 2DNA Diagnostic Laboratory, National Eye Institute, National Institutes of Health, Bethesda, Maryland; 3National Centre of Excellence in
Molecular Biology, University of the Punjab, Lahore, Pakistan; 4The
Wilmer Eye Institute, Johns Hopkins University School of Medicine,
Baltimore, Maryland; 5The Berman-Gund Laboratory for the Study of
Retinal Degenerations, Harvard Medical School, Massachusetts Eye and
Ear Infirmary, Boston, Massachusetts; 6Center for Human Disease Modeling and Department of Cell Biology, Duke University, Durham, North
Carolina; 7Allama Iqbal Medical Research Center, Allama Iqbal Medical
College, Lahore, Pakistan; and 8Service des Maladies Congénitales et
Héréditaires, Hôpital Charles Nicolle, Tunis, Tunisia.
Supported in part by a Center Grant from the Foundation Fighting
Blindness (ELB).
Submitted for publication March 14, 2011; revised April 22, 2011;
accepted May 16, 2011.
Disclosure: J. Chen, None; N. Smaoui, None; M.B.H. Hammer,
None; X. Jiao, None; S.A. Riazuddin, None; S. Harper, None; N.
Katsanis, None; S. Riazuddin, None; H. Chaabouni, None; E.L.
Berson, None; J.F. Hejtmancik, None
Corresponding author: J. Fielding Hejtmancik, Ophthalmic Genetics and Visual Function Branch, National Eye Institute, National Institutes of Health, 5635 Fisher’s Lane, Rockville, MD 20852;
f3h@helix.nih.gov.
mutations in any currently identified BBS genes suggests further genetic heterogeneity. (Invest Ophthalmol Vis Sci. 2011;
52:5317–5324) DOI:10.1167/iovs.11-7554
B
ardet-Biedl syndrome (BBS; MIM 209900) is a genetically
heterogeneous autosomal recessive disorder characterized
by progressive retinal degeneration, truncal obesity, cognitive
impairment, polydactyly, hypogonadism, and renal anomalies.1– 6 Among the nonconsanguineous populations of Northern Europe and America, the prevalence ranges from 1 in
100,000 in North America7 to 1 in 160,000 in Switzerland.8 BBS
incidence increases within populations of high consanguinity
or those that are geographically isolated.4,9,10 To date, 15
genes (BBS112, Meckel syndrome 1 [MKS1, BBS13], centrosomal protein 290 kDa/nephronophthisis 6 [CEP290/NPHP6,
BBS14], and C2ORF86 [BBS15]) have been implicated in
BBS.11,12 Mutations in these genes account only for approximately 70% of BBS patients, suggesting that there are additional
genes to be found for BBS.13BBS1 and BBS10 are major pathogenic genes in European populations, each accounting for at
least 20% of cases in most series.14,15 However, most other
genes are rare contributors. For example, there is only a single
documented family with mutations in each of BBS11 (TRIM32),
BBS13 (MKS1), BBS14 (CEP290), and BBS15 (C2ORF86).12,16,17
A number of recent publications have expanded the spectrum of
known BBS mutations,18 –21 and suggested that mutations in some
genes, including BBS13 and TMEM67/MKS3, can modify the
expression of BBS phenotypes in patients who have mutations in
other genes.
BBS is also characterized by profound interfamilial and intrafamilial clinical variability, which is possibly explained in
part by the presence of second-site modifiers. In some families,
three mutated alleles in two BBS genes have been implicated
(triallelic inheritance). BBS1, BBS2, BBS3, BBS4, BBS5, BBS6,
BBS7, BBS8, and BBS10 have been implicated in triallelic
inheritance of BBS,22–25 but the specific contribution of each
allele is difficult to ascertain. Moreover, it has been suggested
that there might be a connection between triallelism and the
phenotypic severity of the disease.26 However, some studies
have not identified a complex inheritance mode in this syndrome.27,28
In this study, we analyzed 55 families for known BBS genes
(BBS1-BBS15) and identified 43 mutations in 46 families, 21 of
which are novel. We also identified 7 Caucasian, 1 Arabic, and
1 Tunisian family in whom the molecular genetic findings
raised the possibility of triallelic inheritance involving BBS1,
BBS2, BBS3, BBS6, BBS7, BBS8, BBS9, BBS10, or BBS12.
Although some sequence variations were identified in additional genes, no homozygous potential mutations were identified in previously unidentified BBS genes.
Investigative Ophthalmology & Visual Science, July 2011, Vol. 52, No. 8
Copyright 2011 The Association for Research in Vision and Ophthalmology, Inc.
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933462/ on 06/24/2017
5317
5318
Chen et al.
MATERIALS
AND
METHODS
Appropriate informed consent was obtained from all participants in
the study, in accord with the tenets of the Declaration of Helsinki. This
study was approved by the Massachusetts Eye and Ear Infirmary and
Harvard Medical School Institutional Review Boards, the ethics review
board of Charles Nicolle Hospital, Tunis, and the CNS Institutional
Review Board at the National Institutes of Health.
Study Subjects
We studied 70 persons with Bardet-Biedl syndrome (BBS) from 55
unrelated families including 8 recruited in Tunisia, 2 recruited in
Pakistan, and 44 of European and 1 of Arabian descent recruited in the
United States. In this study, the 8 BBS families recruited from Tunisia
did not overlap with participants from a previous study.28 Among the
55 families, 44 were sporadic cases and the remaining had at least 2
affected members. BBS was diagnosed on the basis of the established
criterion that 4 primary features or 3 primary plus 2 secondary features
are necessary to make the diagnosis.29 The control group consisted of
96 persons of European origin, 96 persons of Tunisian origin, and 96
persons of Pakistani origin.
Mutation Screening
We carried out a mutation screen of the first 12 identified BBS (BBS1BBS12) genes in 55 families (for a total of 70 patients) collected from
the United States, Tunisia, and Pakistan. For BBS1 to BBS12, all genes
were screened in all cases. Cases in which no mutations were found in
BBS1 to BBS12 were then screened for mutations in BBS13 (MKS1),
BBS14 (CEP290, NPHP6), and BBS15 (C2ORF86) as well as in
RPGRIP1L, CC2D2A, NPHP3, TMEM67, and INPP5E because they
have been implicated in other ciliopathies. Genomic DNA was isolated
from blood leukocytes using standard protocols.30 Coding regions and
exon-intron boundaries of the 20 genes were amplified by PCR using
standard methods. Amplifications were carried out as previously described,28 and the PCR products were analyzed on 2% agarose gels and
purified by vacuum filtration manifold plate (Millipore, Billerica, MA).
The PCR primers for each exon were used for bidirectional sequencing
using a reaction mix (BigDye Terminator Ready; Applied Biosystems,
Foster City, CA) according to the manufacturer’s instructions. Sequencing was performed on a gene analyzer (ABI PRISM 3130xl
Genetic Analyzer; Applied Biosystems), and sequence traces were
analyzed (MutationSurveyor [Soft Genetics Inc., State College, PA]
and the SeqMan program of DNASTAR Software [DNASTAR Inc.,
Madison, WI]).
Criteria to Determine the Pathogenicity of New
BBS Mutations
A mutation was considered novel if it was not present in the Human
Mutation Database (http://www.hgmd.cf.ac.uk/ac) or the National
Center for Biotechnology Information dbSNP database (http://
www.ncbi.nlm.nih.gov/projects/SNP/index.html) and not published.
A sequence variation was considered pathogenic when it segregated
with the disease in the family and, when parental origin could be
determined, double heterozygous mutations acted in trans; it was not
present in 96 randomly selected controls from the ethnically matched
population; it altered a well-conserved amino acid, preferably in a
conserved region (http://www.ebi.ac.uk/Tools/clustalw2/index.html);
and it was judged significant in a computational test for novel mutations. The neural network splice site scoring program (http://www.
fruitfly.org/seq_tools/splice.html) was used to evaluate the effect of
mutations affecting splice sites. Splice site scores were calculated with
Splice site Score Calculation software (http://rulai.cshl.edu/new_
alt_exon_db2/HTML/score.html). PolyPhen analysis (http://genetics.
bwh.harvard.edu/pph/) was used to predict whether missense variations could impact the protein structure and function. The prediction
is based on the position-specific independent counts score derived
from a combination of available structural information and multiple
IOVS, July 2011, Vol. 52, No. 8
sequence alignments of observations. PolyPhen scores ⬎2.0 indicate
the variant is probably damaging to protein function; scores from 1.5
to 2.0 indicate the variant is possibly damaging; and scores ⬍1.5
indicate the variant is Likely benign. In the present study, both “probably damaging” and “possibly damaging” changes were classified as
suspected pathogenic mutations.
RESULTS
General Overview of BBS Mutations
Mutations were detected in 46 (of 55; 84%) families, and no
mutations were detected for the remaining 9 (of 55; 16%)
families. We identified 43 different mutations in the 46
families, including 39 families from the United States, including 1 of Saudi Arabian derivation, 5 from Tunisia, and 2 from
Pakistan. Of the 43 different mutations, 21 were novel
(Fig. 1, Table 113–15,24 –26,28,31–34), confirming the genetic
heterogeneity of BBS. Seven Caucasian, 1 Arabian, and 1
Tunisian family (20% of families with mutations detected)
carry 3 mutations in 2 different genes, raising the possibility
of triallelic inheritance (Table 1). Thirty-seven families (83%
of patients with mutations detected) carry only 2 mutations
in the same gene (Table 1): 15 for BBS1 (13 homozygotes
and 2 compound heterozygotes), 4 for BBS2 (3 homozygotes and 1 compound heterozygote), 2 homozygotes for
BBS3, 2 homozygotes for BBS5, 3 homozygotes for BBS7, 11
for BBS10 (5 homozygotes and 6 compound heterozygotes),
and 1 compound heterozygote for BBS12 (C4ORF24). None
of the novel mutations or third-allele mutations was observed in 192 ethnically matched control chromosomes, and
none is recorded in the dbSNP database.
BBS1 Mutations
BBS1 mutations were present in 19 of the 46 families with
identified mutations and represented the primary pathogenic
locus in 18 families (33%) and a possible third mutant allele in
1 family (Fig. 1, Table 1). In 15 families (13 homozygotes and
2 compound heterozygotes), only 2 mutations were identified
in the BBS1 gene (Table 1). Eighteen affected members of 12
Caucasian families and 1 Tunisian family were homozygous for
the M390R allele, predicted to be pathogenic with a PolyPhen
score of 2.7. The proband of family D597 is a compound
heterozygote for M390R and c.518⫹1G⬎A, which was not
found in controls and showed calculated splice site scores of
11.0 for the normal splice site and 0.2 for the variant site,
suggesting that it affects splicing. The proband of family 7348
was a compound heterozygote for the M390R and E549X
alleles. All affected members carrying the M390R mutation
shared a common SNP haplotype across the BBS1 gene (Supplementary Table S1, http://www.iovs.org/lookup/suppl/doi:
10.1167/iovs.11-7554/-/DCSupplemental).
Possible triallelic inheritance with involvement of mutations at two distinct loci was seen in 3 European-American
families (K550, J118, and E521) and 1 Tunisian family
(057015) (Table 1), including the proband of family 057015,
who was heterozygous for the F337L allele in BBS8 and
homozygous for the c.1473⫹4A⬎G BBS1 allele, which
showed a reduction from 7.3 for the natural splice site to 4.3
for the variant site, indicating that this alteration might
affect splicing.
BBS2 Mutations
BBS2 mutations were identified in 6 of the 46 families; they
were the primary pathogenic mutations in 5 families (9%)
and a potential triallelic contributor in 1 family. Two were
novel (Fig. 1, Table 1). The proband of family E325 was a
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933462/ on 06/24/2017
BBS Mutations
IOVS, July 2011, Vol. 52, No. 8
5319
FIGURE 1. The 21 novel BBS mutations identified in this study. Three novel
mutations were identified in BBS1: a
heterozygous c.518⫹1G⬎A allele, a homozygous c.1473⫹4A⬎G allele, and a
heterozygous R512H allele. Two novel
mutations were identified in BBS2: a
heterozygous R275X allele and a
heterozygous c.1659⫹3A⬎G allele. A
novel homozygous deletion was identified in BBS3: c.123⫹1118del53985.
Two novel mutations were identified
in BBS5: a homozygous L50R allele
and a homozygous c.619-1G⬎C allele.
One novel mutation was identified in
BBS6: a heterozygous R309H allele.
Three novel mutations were identified
in BBS8: a heterozygous K95R allele, a
heterozygous M135I allele, and a
heterozygous F337L allele. One novel
mutation was identified in BBS9: a
heterozygous Q132H allele. Six novel
mutations were identified in BBS10: a
homozygous L533fsX22 allele, a homozygous A323V allele, a heterozygous
L445I allele, a homozygous E499X allele,
a heterozygousT516RfsX7 allele, and a
heterozygous V602L allele. Two novel
mutations were identified in BBS12: a
heterozygous W520X allele and a
heterozygous R675X allele. Sequence
tracings of novel mutations identified in
this study compared to normal sequences from controls.
compound heterozygote for R275X and D104A and had a
score of 2.44 when analyzed with PolyPhen, suggesting
pathogenicity.
Possible triallelic inheritance with involvement of mutations at two distinct loci was suspected in two Europeanderived families (E729 and K550) (Table 1). The proband of
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933462/ on 06/24/2017
5320
Chen et al.
IOVS, July 2011, Vol. 52, No. 8
TABLE 1. Mutations Identified in this Series of 46 Families (43 Mutations Found)
Family
Ethnic Origin
Gene
Exon
Nucleotide Change
Predicted Amino Acid Change
State
Report/Date
K550
Caucasian
057015
Tunisian*
J118
Caucasian
5360
Caucasian
D257
Caucasian
E729
Caucasian
E059
Arabic
9409
Caucasian
E521
Caucasian
7367
7833
0775
7881
6579
1502
9390
5943
9437
2532
3163
F248
057016
D597
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Tunisian*
Caucasian
7348
Caucasian
1087
E084
Q119
9407
F931
5111
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
9438
Caucasian
F699
Caucasian
2834
Caucasian
E352
Caucasian
9398
Caucasian
E325
Caucasian
057012
M-679
PK01
M-002
057010
J585
B-489
J183
057013
Tunisian*
Caucasian
Pakistani*
Caucasian
Tunisian*
Caucasian
Caucasian
Caucasian
Tunisian*
Pakistani*
16
13
14
11
12
16
5
2
1
2
3
2
15
2
3
5
7
5
1
1
15
12
12
12
12
12
12
12
12
12
12
12
12
12
6
12
12
16
2
2
2
2
2
2
2
2
2
2
2
2
2
1
2
1
2
2
8
5
8
11
8
3
7
7
7
1
1
3
c.1645G⬎T
c.1659⫹3A⬎G†
c.1473⫹4A⬎G†
c.1011C⬎G†
c.1169T⬎G
c.1645G⬎T
c.396G⬎C†
c.1598_1601delTAAC†
c.355G⬎A
c.1090del A
c.926G⬎A†
c.311A⬎C
c.1895G⬎C
c.1333C⬎A†
c.92C⬎T
c.405G⬎A†
c.632C⬎T
c.284A⬎G†
c.2023C⬎T†
c.476C⬎T
c.1535G⬎A†
c.1169T⬎G
c.1169T⬎G
c.1169T⬎G
c.1169T⬎G
c.1169T⬎G
c.1169T⬎G
c.1169T⬎G
c.1169T⬎G
c.1169T⬎G
c.1169T⬎G
c.1169T⬎G
c.1169T⬎G
c.1169T⬎G
c.518⫹1G⬎A†
c.1169T⬎G
c.1169T⬎G
c.1645G⬎T
c.272 insertion T
c.272 insertion T
c.272 insertion T
c.1495G⬎T†
c.968C⬎T†
c.272 insertion T
c.907_910delAGTC
c.272 insertion T
c.907_910delAGTC
c.272 insertion T
c.1677C⬎A
c.687delT†
c.907_910delAGTC
c.145C⬎T
c.1804G⬎C†
c.164T⬎C
c.1543_1546dupGATA†
c.311A⬎C
c.823C⬎T†
c.565C⬎T
c.823C⬎T
c.1658C⬎T
c.619–1G⬎C†
c.149T⬎G†
c.710_713delAGAG
c.632C⬎T
c.632C⬎T
1560G⬎A†
c.355G⬎A
c.123⫹1118del53985†
p.E549X
splice mutation
splice mutation
p.F337L
p.M390R
p.E549X
p.Q132H
p.L533fsX22
p.G119S
p.N364TfsX5
p.R309H
p.D104A
p.R632P
p.L445I
p.T31M
p.M135I
p.T211I
p.K95R
p.R675X
p.P159L
p.R512H
p.M390R
p.M390R
p.M390R
p.M390R
p.M390R
p.M390R
p.M390R
p.M390R
p.M390R
p.M390R
p.M390R
p.M390R
p.M390R
splice mutation
p.M390R
p.M390R
p.E549X
p.C91LfsX5
p.C91LfsX5
p.P.C91LfsX5
p.E499X
p.A323V
p.C91LfsX5
p.S303RfsX3
p.C91LfsX5
p.S303RfsX3
p.C91LfsX5
p.Y559X
p.P229fsX8
p.S303RfsX3
p.R49W
p.V602L
p.L55P
p.T516RfsX7
p.D104A
p.R275X
p.R189X
p.R275X
p.R413X
splice mutation
p.L50R
p.K237fsX60
p.T211I
p.T211I
p.W520X
p.G119S
061049
BBS1
BBS2
BBS1
BBS8
BBS1
BBS1
BBS9
BBS10
BBS12
BBS10
BBS6
BBS2
BBS2
BBS10
BBS3
BBS8
BBS7
BBS8
BBS12
BBS12
BBS1
BBS1
BBS1
BBS1
BBS1
BBS1
BBS1
BBS1
BBS1
BBS1
BBS1
BBS1
BBS1
BBS1
BBS1
BBS1
BBS1
BBS1
BBS10
BBS10
BBS10
BBS10
BBS10
BBS10
BBS10
BBS10
BBS10
BBS10
BBS10
BBS10
BBS10
BBS10
BBS10
BBS10
BBS10
BBS2
BBS2
BBS2
BBS2
BBS2
BBS5
BBS5
BBS7
BBS7
BBS7
BBS12
BBS12
BBS3
Homozygous
Heterozygous
Homozygous
Heterozygous
Heterozygous
Heterozygous
Heterozygous
Homozygous
Heterozygous
Homozygous
Heterozygous
Heterozygous
Heterozygous
Heterozygous
Homozygous
Heterozygous
Homozygous
Heterozygous
Heterozygous
Heterozygous
Heterozygous
Homozygous
Homozygous
Homozygous
Homozygous
Homozygous
Homozygous
Homozygous
Homozygous
Homozygous
Homozygous
Homozygous
Homozygous
Homozygous
Heterozygous
Heterozygous
Heterozygous
Heterozygous
Homozygous
Homozygous
Homozygous
Homozygous
Homozygous
Heterozygous
Heterozygous
Heterozygous
Heterozygous
Heterozygous
Heterozygous
Heterozygous
Heterozygous
Heterozygous
Heterozygous
Heterozygous
Heterozygous
Heterozygous
Heterozygous
Homozygous
Homozygous
Homozygous
Homozygous
Homozygous
Homozygous
Homozygous
Homozygous
Heterozygous
Heterozygous
Homozygous
Ref. 14/2002
This study
This study
This study
Ref. 27/2003
Ref. 14/2002
This study
This study
Ref. 34/2010
Ref. 40/2007
This study
Ref. 25/2001
Ref. 26/2009
This study
Ref. 41/2004
This study
Ref. 42/2003
This study
This study
Ref. 13/2007
This study
Ref. 14/2002
Ref. 14/2002
Ref. 14/2002
Ref. 14/2002
Ref. 14/2002
Ref. 14/2002
Ref. 14/2002
Ref. 14/2002
Ref. 14/2002
Ref. 14/2002
Ref. 14/2002
Ref. 14/2002
Ref. 14/2002
This study
Ref. 27/2003
Ref. 27/2003
Ref. 14/2002
Ref. 15/2006
Ref. 15/2006
Ref. 15/2006
This study
This study
Ref. 15/2006
Ref. 15/2006
Ref. 15/2006
Ref. 15/2006
Ref. 15/2006
Ref. 34/2010
Ref. 15/2006
Ref. 15/2006
Ref. 15/2006
This study
Ref. 34/2010
This study
Ref. 25/2001
This study
Ref. 28/2006
Ref. 25/2001
Ref. 24/2003
This study
This study
Ref. 42/2003
Ref. 42/2003
Ref. 42/2003
This study
Ref. 34/2010
This study
* DNA samples from the Tunisian and Pakistani families were obtained through the National Eye Institute; all others were obtained through
the Berman-Gund Laboratory, Harvard Medical School, Massachusetts Eye and Ear Infirmary.
† Novel mutations.
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933462/ on 06/24/2017
BBS Mutations
IOVS, July 2011, Vol. 52, No. 8
5321
FIGURE 2. Amino acid sequence conservation around residues affected by novel missense mutations in BBS1, BBS5, BBS6, BBS8, BBS9, and BBS10
identified in this study. Asterisk: position of the missense mutation. The sequences of BBS proteins or predicted translation products from several
species have been compared and aligned. The relevant amino acids are in bold, and they are underlined when different from Homo sapiens
reference; other identities are represented by a gray background. Homo, H. sapiens; Mus, Mus musculus; Rattus, Rattus norvegicus; Xenopus,
Xenopus (silurana) tropicalis; Danio, Danio rerio; Bos, Bos taurus; Pongo, Pongo abelii; Gallus, gallus; Pan, Pan troglodytes; Equus, Equus
caballus.
family E729 was a compound heterozygote for the D104A and
R632P (PolyPhen scores of 2.44 and 2.7, respectively) alleles
and also carried a heterozygous L445I allele in BBS10. The proband of family K550 was heterozygous for the c.1659⫹3A⬎G
BBS2 allele (decreasing the splice site score from 0.52 to 0,
consistent with loss of the donor site) and also carried a homozygous E549X allele in BBS1, the principal “pathogenic” mutation.
BBS3 Mutations
BBS3 mutations were found in 2 of the 46 families (4%),
including a consanguineous Pakistani family (061049) in which
affected members were homozygous for a novel 54-kb deletion
beginning in intron 3, c.123⫹1118del 53,985, and extending
beyond the end of the gene. In an Arabian family (E059),
affected members were homozygous for a previously reported
T31M allele in BBS3, predicted to be pathogenic (PolyPhen
score 2.78). One member of this family also had a heterozygous
M135I allele in BBS8 predicted to be benign with a PolyPhen
score of 1.09.
BBS6 Mutations
A novel heterozygous sequence change was present in a single
family of European origin (D257), which showed the R309H
BBS6 allele and carried a homozygous N364TfsX5 allele in
BBS10 as well (Table 1), suggesting the possibility of triallelic
inheritance. However, the R309H residue was not highly conserved during evolution (Fig. 2), and PolyPhen analysis predicts
R309H to be benign (Table 2), indicating that its pathogenic
potential is low.
BBS7 Mutations
Previously described BBS7 mutations were present in 4 of the
46 families (7%), all of European origin. Possible triallelic inheritance is suspected in 1 family (9409; Table 1), in which 2
affected family members are homozygous for theT211I
BBS7allele and heterozygous for the K95R sequence change in
BBS8. However, the K95R residue was not highly conserved
during evolution (Fig. 2), and PolyPhen analysis predicts K95R
to be benign with a score of 0.15 (Table 2).
BBS5 Mutations
Novel BBS5 mutations were found in 2 of the 46 families (4%),
including a homozygous c.619 –1G⬎C allele in European family M-002, decreasing the splice site score from 5.6 to ⫺5.4
(Fig. 1, Table 1). Tunisian family 057010 showed a homozygous L50R (probably pathogenic) sequence change with a
PolyPhen score of 2.17. Both mutations reported here affected
the highly conserved DM16 domains,35 supporting their pathogenicity.
BBS8 Mutations
Novel heterozygous BBS8 sequence changes were identified in
3 of the 46 families (6%; M135I in E059, K95R in Arabian family
9409, and F337L in Tunisian family 057015), all of which may
be compatible with triallelic inheritance. The M135I residue is
highly conserved during evolution, but PolyPhen predicts
M135I to be benign with a score of 1.09 (Fig. 2, Table 2). In
contrast, the F337L residue is highly conserved during evolu-
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933462/ on 06/24/2017
5322
Chen et al.
IOVS, July 2011, Vol. 52, No. 8
TABLE 2. Evaluation of Novel BBS Missense Variants
Computational Prediction
Gene-Exon
Predicted
Amino Acid
Change
Nucleotide
Change
BBS1-EX15
BBS10-EX2
BBS10-EX2
BBS10-EX2
BBS5-EX3
BBS6-EX3
BBS8_EX5
BBS8_EX5
BBS8-EX11
BBS9-EX5
R512H
A323V
L445I
V602L
L50R
R309H
K95R
M135I
F337L
Q132H
c.1535G⬎A
c.968C⬎T
c.1333C⬎A
c.1804G⬎C
c.149T⬎G
c.926G⬎A
c.284A⬎G
c.405G⬎A
c.1011C⬎G
c.396G⬎C
State
Third
Mutated
Allele
Conserved
PolyPhen
Prediction
Remark
Present in
Controls
Report
Heter
Homo
Heter
Heter
Homo
Heter
Heter
Heter
Heter
Heter
No
No
Yes
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
No
No
Yes
Yes
Yes
Possibly damaging
Likely benign
Likely benign
Likely benign
Probably damaging
Likely benign
Likely benign
Likely benign
Probably damaging
Possibly damaging
Pathogenic
Neutral
Neutral
Neutral
Pathogenic
Neutral
Neutral
Neutral
Pathogenic
Pathogenic
No
No
No
No
No
No
No
No
No
No
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
Heter, heterozygous; Homo, homozygous.
tion (Fig. 2), and PolyPhen analysis indicates that F337L is
expected to be pathogenic with a score of 2.43 (Table 2).
BBS9 Mutations
A novel heterozygous BBS9 sequence change was present in 1
European-derived family (J118), possibly consistent with triallelic inheritance. The Q132H residue is highly conserved during evolution (Fig. 2), and PolyPhen analysis predicts that
Q132H would be expected to be pathogenic with a score of
1.92 (Table 2).
BBS10 Mutations
BBS10 mutations were present in 14 of the 46 families, all European derived, with 2 pathogenic alleles present in 11 (20%), 2
changes of uncertain significance in 2 more (4%), and a single
heterozygous change in 1 family. Six are novel (Fig. 1, Table 1).
The proband of family F931was homozygous for the A323V allele,
which is highly conserved during evolution, but it is a conservative change that PolyPhen analysis predicts to be benign, (Fig. 2,
Table 2). Similarly, the proband of family E352 was a compound
heterozygote for the R49W (previously reported15 with a probably damaging PolyPhen score of 2.46) and V602L alleles. Although
the V602L residue is highly conserved during evolution, PolyPhen
analysis predicts V602L to be benign. The proband of family 9398
was a compound heterozygote for the T516RfsX7 and L55P alleles. The L55P residue is highly conserved during evolution (Fig.
2), with a probably damaging PolyPhen score of 2.07 (Table 2).
Possible triallelic inheritance was found in probands of 3
families: 5360, which, in addition to homozygous L533fsX22,
carries a heterozygous G119S allele in BBS12; D257 is homozygous for the N364TfsX5BBS10 allele with a heterozygous
R309H allele in BBS6; and E729; Table 1). The proband of
family E729 was heterozygous for the L445I BBS10 allele and
also was a compound heterozygote for the D104A and R632P
alleles in BBS2, the principal pathogenic mutations. The L445I
residue is not highly conserved during evolution (Fig. 2), and
PolyPhen predicts L445I to be benign (Table 2), suggesting low
pathogenic potential.
BBS12 (C4ORF24) Mutations
BBS12 mutations (4 different alleles) were present in three
families, including 2 families of European and 1 of Tunisian
origin (Table 1). Possible triallelic inheritance was found in
probands of 2 European-derived families. E521 carries a compound heterozygote for the previously reported13P159L and
R675X alleles and a heterozygous R512H allele in BBS1. The
proband of family 5360 is homozygous L533fsX22 allele in
BBS10 and heterozygous for theBBS12 G119S allele, which is
highly conserved during evolution (Fig. 2) and gives a probably
damaging PolyPhen score (Table 2).
BBS4, BBS11 (TRIM32), BBS13, BBS14, BBS15
(C2ORF86), RPGRIP1L, CC2D2A, NPHP3,
TMEM67, and INPP5E Mutations
No mutations were detected for BBS4, BBS11 (TRIM32),
BBS13, BBS14, BBS15 (C2ORF86), RPGRIP1L, CC2D2A,
NPHP3, TMEM67, or INPP5E in any of the 55 families studied.
DISCUSSION
In agreement with previous studies in which mutations were
identified in 70% to 75% of BBS families,19 –21,36,37 in our study,
mutations were identified in 38 of 45 patients of European
ethnic origin (84%) and 5 of 8 Tunisian families (62.5%), giving
an overall detection rate of 73%.
Our results are consistent with previous reports that BBS1
and BBS10 mutations are frequent, contributing 30% and 21%
in previous studies15,22,23 (Supplementary Fig. S1, http://
www.iovs.org/lookup/suppl/doi:10.1167/iovs.11-7554/-/
DCSupplemental). In this series BBS1 mutations contributed to
disease in35% (19/55) of the patients, representing the primary
pathogenic locus in 18 families (33%). Overall, these data
support the previous observation that BBS1 and BBS10 are
responsible for most of the disease in Europeans. In contrast,
BBS2 and BBS8 are prime candidates in Tunisian-derived patients, in whom no BBS10 mutations were identified.
Examination of the distribution of BBS mutations in European and Tunisian individuals shows a number of differences
(Supplementary Fig. S2, http://www.iovs.org/lookup/suppl/
doi:10.1167/iovs.11-7554/-/DCSupplemental). In agreement
with previous reports, in which p.M390R has been reported to
cause 18% to 32% of BBS cases,22,27 16 of 55 (29%) of families
with BBS were found to carry the M390R mutation (13 as
homozygous alleles and 3 as heterozygous alleles), making it
the most common mutation found. It accounts for 24 of 32
(75%) BBS1 alleles identified in Europeans, in which the
M390R mutation is considered to be an ancient mutation, as
suggested by haplotype analysis. The M390R mutation has
been described exclusively in European-derived patients of
French descent.27 Interestingly, although 1 Tunisian patient in
this study carries this mutation, he shares a common BBS1 SNP
haplotype with the European patients. The geographic position of Tunisia in North Africa has ensured an eventful population history in which Phoenicians, Romans, Vandals, Byzan-
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933462/ on 06/24/2017
BBS Mutations
IOVS, July 2011, Vol. 52, No. 8
tines, Arabs, Ottomans, and French have controlled or
colonized the region at different historical times.28 Taken together with the haplotype data, this suggests that this Tunisian
patient might be of French descent, consistent with the absence of the M390R mutation in most non-European populations. BBS2 and BBS8 are the most common genes implicated
in Tunisians, and R189X is the only BBS2 mutation seen in
Tunisians. Finally, though the Tunisian data set is relatively
small, it is notable for the complete absence of BBS10 mutations, the second most common gene affected in Europeans
after BBS1.
BBS is inherited primarily as an autosomal recessive trait.
However, in some patients, 3 mutations across 2 BBS genes
appear to interact to modify the onset or severity, or both, of
the phenotype.22–25Seven Caucasian families, 1 Arabian family,
and 1 Tunisian family (15% of patients with mutations detected) were found to carry 3 mutations in the 2 different
genes, termed triallelic inheritance (Supplementary Fig. S3,
http://www.iovs.org/lookup/suppl/doi:10.1167/iovs.117554/-/DCSupplemental). We found only a single, heterozygous mutation in BBS1 in 3 families, in BBS10 in 2 families, and
in BBS2, BBS3, BBS7, and BBS12 in single families (Table 1).
Although these data are compatible with a potential epistatic
interaction, in which the effects of the primary gene are modified by a specific allele at a second gene, they might also
represent the presence of undetected second mutations or the
random occurrence of sequence variants in these genes.
Interestingly, 8 of the 9 third variant alleles were novel,
except for BBS12 p.G119S, which was reported recently as a
third allele variant by Billingsley et al.31 (Table 1, Supplementary Fig. S3, http://www.iovs.org/lookup/suppl/doi:10.1167/
iovs.11-7554/-/DCSupplemental), and 2 of them involve genes
that, to our knowledge, have not previously been reported to
be involved in triallelic inheritance of BBS (BBS9 and BBS12).
Given that most of these sequence changes are missense variants, the possibility that some are benign cannot be excluded,
even though they were not identified in 96 healthy persons. Of
the 8 missense variants, 4 (R512H in BBS1, F337L in BBS8,
Q132H in BBS9, and G119S in BBS12) were estimated to be
pathogenic changes, whereas the remaining four (R309H in
BBS6, K95R in BBS8, M135I in BBS8, and L445I in BBS10)
were estimated to be neutral by the PolyPhen program (Table
2). Five, including all those predicted to be pathogenic by
PolyPhen analysis, involve residues that are highly conserved
during evolution (Fig. 2). Thus, alternative explanations must
be considered, including that the third allele detected in each
of the families is a benign polymorphism or that the third allele
is not causal in these patients but might exert a more subtle
modifying effect. These observations are compatible with
the previous suggestion that the severity of the disease phenotype and the clinical symptoms may vary as a result of the
interaction of mutations in different BBS genes.22,23 However,
the absence of these variants in 96 ethnically matched control
subjects does not provide sufficient statistical power to demonstrate a causal relationship to BBS; functional analysis will be
required to provide a definitive answer to this question.
Recent studies provide insight into how the BBS proteins
mediate ciliary function in mammalian cells. Seven evolutionarily conserved BBS proteins (BBS1, 2, 4, 5, 7, 8, and 9) form a
stable complex, the BBSome, mediating vesicular transport to
the cilium.38 The BBSome is transported to the basal body
through interactions between the BBS4 subunit of the BBSome
and PCM-1 of the centriolar satellite. Inside the cilium, BBS7
and TTC8 may be involved in vesicular transport pathways,
including functioning as an IFT cohesion factor.38 The ability of
each BBS locus to contribute alleles that can modify the effect
of mutations in other BBS genes suggests a common pathway
and potentially the existence of a macromolecular complex
5323
under the “poison” hypothesis, stating the presence of mutant
subunits in a heterodimer or multisubunit complex prevents
proper functioning of the entire assembly.39 Although BBS6,
BBS10, and BBS12 are not components of the BBSome, mutations in these genes also lead to similar phenotypes. Seo et al.40
demonstrated that chaperonin-like BBS proteins (BBS6, BBS10,
and BBS12) are required for BBSome assembly.
In addition to BBS, a number of related syndromes result
from ciliary dysfunction, including BBS14 mutated in
nephronophthisis, Joubert syndrome, and BBS and MeckelGruber syndrome.17,41,42 Although this provided a rationale
for screening families without identified mutations in known
BBS genes for mutations in these genes, no mutations were
found in our patients.
In summary, we have identified 43 mutations in 55 families
affected with BBS, including 21 novel mutations. We found
evidence compatible with triallelic inheritance in affected persons from 9 families. This mutational analysis has expanded the
already extensive categorization of BBS mutations and contributed to our understanding of both the population genetics of
BBS and to the molecular pathology of the genes implicated in
these diseases, as well as suggesting distinct optimal sequential
mutational analysis in Tunisian and European patients for diagnostic purposes. The identification of many novel mutations
unique to individuals highlights the genetic heterogeneity of
the disorder, and the existence of some BBS cases without
identified mutations in known BBS genes suggests further
genetic heterogeneity.
Acknowledgments
The authors thank all the patients and their families for their contribution to this work.
References
1. Laurence JZ, Moon RC. Four cases of “retinitis pigmentosa” occurring in the same family and accompanied by general imperfection
of development. Ophthal Rev.1866;2:32– 41.
2. Bardet G. Sur un syndrome d’obesite infantile avec polydactylie et
retinite pigmentaire (contribution a l’etude des formes cliniques
de l’obesite hypophysaire). 1920.
3. Biedl A. Ein Geschwisterpaar mit adiposo-genitaler Dystrophie.
Dtsch. Med Wschr. 1922;48:1630 –1630.
4. Moore SJ, Green JS, Fan Y, et al. Clinical and genetic epidemiology
of Bardet-Biedl syndrome in Newfoundland: a 22-year prospective,
population-based, cohort study. Am J Med Genet A. 2005;132:352–
360.
5. Rizzo JF III, Berson EL, Lessell S. Retinal and neurologic findings in the
Laurence-Moon-Bardet-Biedl phenotype. Ophthalmology. 1986;93:
1452–1456.
6. Bell J. Anomalies and diseases of the eye. In: Pearson K (ed),
Treasury of Human Inheritance: Dulau and Cow Ltd.; 1909.
7. Croft JB, Swift M. Obesity, hypertension, and renal disease in
relatives of Bardet-Biedl syndrome sibs. Am J Med Genet. 1990;36:
37– 42.
8. Klein D, Ammann F. The syndrome of Laurence-Moon-Bardet-Biedl
and allied diseases in Switzerland: clinical, genetic and epidemiological studies. J Neurol Sci. 1969;9:479 –513.
9. Farag TI, Teebi AS. Bardet-Biedl and Laurence-Moon syndromes in
a mixed Arab population. Clin Genet. 1988;33:78 – 82.
10. Farag TI, Teebi AS. High incidence of Bardet Biedl syndrome
among the Bedouin. Clin Genet. 1989;36:463– 464.
11. Zaghloul NA, Katsanis N. Mechanistic insights into Bardet-Biedl
syndrome, a model ciliopathy. J Clin Invest. 2009;119:428 – 437.
12. Kim SK, Shindo A, Park TJ, et al. Planar cell polarity acts through
septins to control collective cell movement and ciliogenesis. Science. 2010;329,1337–1340.
13. Stoetzel C, Muller J, Laurier V, et al. Identification of a novel BBS
gene (BBS12) highlights the major role of a vertebrate-specific
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933462/ on 06/24/2017
5324
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
Chen et al.
branch of chaperonin-related proteins in Bardet-Biedl syndrome.
Am J Hum Genet. 2007;80:1–11.
Mykytyn K, Nishimura DY, Searby CC, et al. Identification of the
gene (BBS1) most commonly involved in Bardet-Biedl syndrome, a
complex human obesity syndrome. Nat Genet. 2002;31:435– 438.
Stoetzel C, Laurier V, Davis EE, et al. BBS10 encodes a vertebratespecific chaperonin-like protein and is a major BBS locus. Nat
Genet. 2006;38:521–524.
Chiang AP, Beck JS, Yen HJ, et al. Homozygosity mapping with
SNP arrays identifies TRIM32, an E3 ubiquitin ligase, as a BardetBiedl syndrome gene (BBS11). Proc Natl Acad Sci U S A. 2006;
103:6287– 6292.
Leitch CC, Zaghloul NA, Davis EE, et al. Hypomorphic mutations in
syndromic encephalocele genes are associated with Bardet-Biedl
syndrome. Nat Genet. 2008;40:443– 448.
Abu Safieh L, Aldahmesh M, Shamseldin H, et al. Clinical and
molecular characterization of Bardet-Biedl syndrome in consanguineous populations: the power of homozygosity mapping. J Med
Genet. 2009;47:236 –241.
Muller J, Stoetzel C, Vincent MC, et al. Identification of 28 novel
mutations in the Bardet-Biedl syndrome genes: the burden of
private mutations in an extensively heterogeneous disease. Hum
Genet. 2010;127:583–593.
Hjortshoj TD, Gronskov K, Philp AR, et al. Bardet-Biedl syndrome
in Denmark—report of 13 novel sequence variations in six genes.
Hum Mutat. 2010;31:429 – 436.
Harville HM, Held S, az-Font A, et al. Identification of 11 novel
mutations in 8 BBS genes by high-resolution homozygosity mapping. J Med Genet. 2009;47:262–267.
Badano JL, Kim JC, Hoskins BE, et al. Heterozygous mutations in
BBS1, BBS2 and BBS6 have a potential epistatic effect on BardetBiedl patients with two mutations at a second BBS locus. Hum Mol
Genet. 2003;12:1651–1659.
Beales PL, Badano JL, Ross AJ, et al. Genetic interaction of BBS1
mutations with alleles at other BBS loci can result in non-Mendelian Bardet-Biedl syndrome. Am J Hum Genet. 2003;72:1187–
1199.
Fauser S, Munz M, Besch D. Further support for digenic inheritance in Bardet-Biedl syndrome. J Med Genet. 2003;40:e104.
Katsanis N, Ansley SJ, Badano JL, et al Triallelic inheritance in
Bardet-Biedl syndrome, a Mendelian recessive disorder. Science.
2001;293:2256 –2259.
Bin J, Madhavan J, Ferrini W, Mok CA, Billingsley G, Heon E. BBS7
and TTC8 (BBS8) mutations play a minor role in the mutational
load of Bardet-Biedl syndrome in a multiethnic population. Hum
Mutat. 2009;30:E737–E746.
Mykytyn K, Nishimura DY, Searby CC, et al. Evaluation of complex
inheritance involving the most common Bardet-Biedl syndrome
locus (BBS1). Am J Hum Genet. 2003;72:429 – 437.
IOVS, July 2011, Vol. 52, No. 8
28. Smaoui N, Chaabouni M, Sergeev YV, et al. Screening of the eight
BBS genes in Tunisian families: no evidence of triallelism. Invest
Ophthalmol Vis Sci. 2006;47:3487–3495.
29. Beales PL, Elcioglu N, Woolf AS, Parker D, Flinter FA. New criteria
for improved diagnosis of Bardet-Biedl syndrome: results of a
population survey. J Med Genet. 1999;36:437– 446.
30. Smith RJH, Holcomb JD, Daiger SP, et al. Exclusion of Usher
syndrome gene from much of chromosome 4. Cytogenet Cell
Genet. 1989;50:102–106.
31. Billingsley G, Bin J, Fieggen KJ, et al. Mutations in chaperonin-like
BBS genes are a major contributor to disease development in a
multiethnic Bardet-Biedl syndrome patient population. J Med
Genet. 2010;47:453– 463.
32. White DR, Ganesh A, Nishimura D, et al. Autozygosity mapping of
Bardet-Biedl syndrome to 12q21.2 and confirmation of FLJ23560 as
BBS10. Eur J Hum Genet. 2007;15:173–178.
33. Fan Y, Esmail MA, Ansley SJ, et al. Mutations in a member of the
Ras superfamily of small GTP-binding proteins causes Bardet-Biedl
syndrome. Nat Genet. 2004;36:989 –993.
34. Badano JL, Ansley SJ, Leitch CC, Lewis RA, Lupski JR, Katsanis N.
Identification of a novel Bardet-Biedl syndrome protein, BBS7, that
shares structural features with BBS1 and BBS2. Am J Hum Genet.
2003;72:650 – 658.
35. Li JB, Gerdes JM, Haycraft CJ, et al. Comparative genomics identifies a flagellar and basal body proteome that includes the BBS5
human disease gene. Cell. 2004;117:541–552.
36. Sapp JC, Nishimura D, Johnston JJ, et al. Recurrence risks for
Bardet-Biedl syndrome: Implications of locus heterogeneity. Genet
Med. 2010;12:623– 627.
37. Janssen S, Ramaswami G, Davis EE, et al. Mutation analysis in
Bardet-Biedl syndrome by DNA pooling and massively parallel
resequencing in 105 individuals. Hum. Genet. 2011;129:79 –90.
38. Nachury MV, Loktev AV, Zhang Q, et al. A core complex of BBS
proteins cooperates with the GTPase Rab8 to promote ciliary
membrane biogenesis. Cell. 2007;129:1201–1213.
39. Badano JL, Katsanis N. Beyond Mendel: an evolving view of human
genetic disease transmission. Nat Rev Genet. 2002;3:779 –789.
40. Seo S, Baye LM, Schulz NP, et al. BBS6, BBS10, and BBS12 form
a complex with CCT/TRiC family chaperonins and mediate
BBSome assembly. Proc Natl Acad Sci U S A. 2010;107:1488 –
1493.
41. Sayer JA, Otto EA, O’Toole JF, et al. The centrosomal protein
nephrocystin-6 is mutated in Joubert syndrome and activates transcription factor ATF4. Nat Genet. 2006;38:674 – 681.
42. Baala L, Audollent S, Martinovic J, et al. Pleiotropic effects of
CEP290 (NPHP6) mutations extend to Meckel syndrome. Am J
Hum Genet. 2007;81:170 –179.
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933462/ on 06/24/2017